These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

560 related items for PubMed ID: 24762462

  • 1. Acute and chronic cardiovascular effects of hyperkalemia: new insights into prevention and clinical management.
    McCullough PA, Beaver TM, Bennett-Guerrero E, Emmett M, Fonarow GC, Goyal A, Herzog CA, Kosiborod M, Palmer BF.
    Rev Cardiovasc Med; 2014; 15(1):11-23. PubMed ID: 24762462
    [Abstract] [Full Text] [Related]

  • 2. Novel Agents for the Prevention and Management of Hyperkalemia.
    McCullough PA, Costanzo MR, Silver M, Spinowitz B, Zhang J, Lepor NE.
    Rev Cardiovasc Med; 2015; 16(2):140-55. PubMed ID: 26198561
    [Abstract] [Full Text] [Related]

  • 3. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Raebel MA.
    Cardiovasc Ther; 2012 Jun; 30(3):e156-66. PubMed ID: 21883995
    [Abstract] [Full Text] [Related]

  • 4. [Electrolyte and acid-base balance disorders in advanced chronic kidney disease].
    Alcázar Arroyo R.
    Nefrologia; 2008 Jun; 28 Suppl 3():87-93. PubMed ID: 19018744
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR, Rolfe M.
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
    [Abstract] [Full Text] [Related]

  • 7. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
    Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B, OPAL-HK Investigators.
    N Engl J Med; 2015 Jan 15; 372(3):211-21. PubMed ID: 25415805
    [Abstract] [Full Text] [Related]

  • 8. New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.
    Tamargo J, Caballero R, Delpón E.
    Cardiovasc Drugs Ther; 2018 Feb 15; 32(1):99-119. PubMed ID: 29372448
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Hyperkalemia in Heart Failure.
    Sarwar CM, Papadimitriou L, Pitt B, Piña I, Zannad F, Anker SD, Gheorghiade M, Butler J.
    J Am Coll Cardiol; 2016 Oct 04; 68(14):1575-89. PubMed ID: 27687200
    [Abstract] [Full Text] [Related]

  • 11. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
    Khosla N, Kalaitzidis R, Bakris GL.
    Am J Nephrol; 2009 Oct 04; 30(5):418-24. PubMed ID: 19738369
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Potential New Agents for the Management of Hyperkalemia.
    Packham DK, Kosiborod M.
    Am J Cardiovasc Drugs; 2016 Feb 04; 16(1):19-31. PubMed ID: 26156040
    [Abstract] [Full Text] [Related]

  • 15. Role of Hyperkalemia in Heart Failure and the Therapeutic Use of Potassium Binders.
    Sarwar CMS, Bhagat AA, Anker SD, Butler J.
    Handb Exp Pharmacol; 2017 Feb 04; 243():537-560. PubMed ID: 28382468
    [Abstract] [Full Text] [Related]

  • 16. [Hyporeninemic hypoaldosteronism and the differential diagnosis of hyperkalemia].
    Weidmann P.
    Schweiz Med Wochenschr; 1982 Dec 04; 112(49):1764-74. PubMed ID: 6758113
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Sodium zirconium cyclosilicate (ZS-9) for the treatment of hyperkalemia.
    Rafique Z, Peacock WF, LoVecchio F, Levy PD.
    Expert Opin Pharmacother; 2015 Dec 04; 16(11):1727-34. PubMed ID: 26159448
    [Abstract] [Full Text] [Related]

  • 20. A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient.
    Ash SR, Singh B, Lavin PT, Stavros F, Rasmussen HS.
    Kidney Int; 2015 Aug 04; 88(2):404-11. PubMed ID: 25651363
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.